Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
In the last 90 days, Cogent Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 325 institutions reported holding it in 13F filings for Q2 2026, worth $7.50B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:54 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 17, 2026 | Feb 25, 2025 | Feb 26, 2024 | Mar 14, 2023 | Mar 15, 2022 |
| Research and development | $269.8M | $232.7M | $173.8M | $121.6M | $55.9M |
| Selling, general and administrative | $63.6M | $43.3M | $34.4M | $26.2M | $19.6M |
| Operating income | -$333.4M | -$275.9M | -$208.1M | -$147.8M | -$75.6M |
| Income tax | $0 | – | – | – | – |
| Net income | -$328.9M | -$255.9M | -$192.4M | -$140.2M | -$72.3M |
| EPS, basic | $-2.16 | $-1.94 | $-2.42 | $-2.39 | – |
| EPS, diluted | $-2.16 | $-1.94 | $-2.42 | $-2.39 | – |
| Weighted shares, basic | 128.9M | 103.9M | 79.7M | 58.7M | – |
| Weighted shares, diluted | 128.9M | 103.9M | 79.7M | 58.7M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 17, 2026 | Feb 25, 2025 | Feb 26, 2024 | Mar 14, 2023 | Mar 15, 2022 |
| Cash and equivalents | $312.0M | $98.2M | $53.2M | $139.9M | $219.7M |
| Total current assets | $910.4M | $296.5M | $270.8M | $265.0M | $222.6M |
| Property, plant and equipment | $5.46M | $6.47M | $8.34M | $7.78M | $1.71M |
| Total assets | $937.6M | $327.9M | $313.4M | $300.8M | $232.1M |
| Accounts payable | $9.50M | $12.0M | $10.7M | $5.84M | $3.48M |
| Total current liabilities | $64.0M | $55.7M | $38.2M | $26.8M | $17.1M |
| Long-term debt | $222.9M | – | – | – | – |
| Total liabilities | $301.2M | $71.6M | $55.6M | $45.1M | $17.9M |
| Shareholders' equity | $636.4M | $256.3M | $257.8M | $255.7M | $214.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 17, 2026 | Feb 25, 2025 | Feb 26, 2024 | Mar 14, 2023 | Mar 15, 2022 |
| Operating cash flow | -$264.4M | -$207.8M | -$153.6M | -$118.6M | -$58.8M |
| Capital expenditures | $1.55M | $573.0K | $2.80M | $6.86M | $1.72M |
| Free cash flow | -$266.0M | -$208.4M | -$156.4M | -$125.5M | -$60.5M |
| Depreciation and amortization | $2.60M | $2.50M | $2.27M | $842.0K | $147.0K |
| Stock-based compensation | $46.1M | $39.7M | $30.6M | $18.4M | $11.7M |
| Investing cash flow | -$399.5M | $38.3M | -$97.8M | -$124.7M | -$1.72M |
| Financing cash flow | $878.2M | $214.5M | $163.5M | $163.6M | $38.0M |
| Net change in cash | $214.3M | $44.9M | -$87.9M | -$79.8M | -$22.5M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 174.0M | +22.2% | SEC |
| Aug 6, 2026 | 173.5M | +24.2% | SEC |
| May 1, 2026 | 170.9M | +50.1% | SEC |
| Feb 13, 2026 | 162.3M | +42.6% | SEC |
| Nov 5, 2025 | 142.4M | +28.9% | SEC |
| Aug 1, 2025 | 139.7M | +27.6% | SEC |
| May 2, 2025 | 113.9M | +19.1% | SEC |
| Feb 21, 2025 | 113.9M | +9.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.